AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

PAYS · NASDAQ · Specialty Business Services

Paysign

Runs prepaid payment programs for plasma centers, drugmakers, and healthcare clients.

$12.80

After-hours close−0.08 (−0.59%)

At close$12.88(−2.13%)

Something off on this page? Send us feedback.

Profile

PaySign, Inc.PAYSIndustrials

Manages prepaid-card and software programs for donor compensation, pharmaceutical patient affordability, and other business disbursements. Revenue is reported as one segment, with recent operations centered on plasma and pharma workflows in the United States.

Built around prepaid-card issuing, processing, and program management, the business serves plasma collection centers, pharmaceutical patient-affordability programs, and smaller corporate disbursement uses. Product names in context include patient affordability solutions, disbursement solutions, Paysign Premier digital banking, incentive solutions, and Apherion donor-management software.

Operations are concentrated in the United States, with headquarters in Henderson, Nevada. The latest filing reports one operating and reportable segment, so product-line economics are visible mainly through plasma, pharma, and other revenue-line disclosures rather than separate segment reporting.

Execution depends on regulated funds flow, payment-network rules, healthcare copay-assistance requirements, data security, and integration of the Gamma donor-engagement assets.

Company facts

CEOMark Newcomer

ListedOct 10, 2007

ExchangeNASDAQ

HeadquartersHenderson, NV

CountryUnited States

Employees226

CIK0001496443

ISINUS70451A1043

Key statistics

Market cap$720.6M

EPS (ttm)$0.2580

P/E (ttm)49.96

ROE30.1%

P/B11.97

P/S7.16

Dividend yield—

Beta0.91vs XLI −0.55

Year to date +160% · Average volume (30d) 731.7K

Analysts

Price target, next 12 months$13.00+0.9%Median of 8 analysts · vs the Aug 28 close

ConsensusBuy5 of 8 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $12.89

High$15.00+16.4%

Median$13.00+0.9%

Low$12.00−6.9%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Rating	Prior target	Target
Aug 11, 2026	Barrington	Target		$11	$15
Aug 6, 2026	DA Davidson	Reiterate	Buy	$9	$12
Aug 6, 2026	Lake Street	Reiterate	Buy		$13
Aug 3, 2026	Barrington	Target			$11

Earnings

EPS

Estimate$0.09

ReportedDue Nov 11, 2026

Revenue

Estimate$29.0M

ReportedDue Nov 11, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 5, 2026Q2 FY26	$0.06	$0.11	+83.3%	$26.4M	$28.3M	+7.2%	+29.30%
May 12, 2026Q1 FY26	$0.07	$0.09	+28.6%	$27.0M	$28.0M	+3.8%	−12.33%
Mar 24, 2026Q4 FY25	$0.02	$0.02	0.0%	$21.5M	$22.8M	+5.6%	+36.60%
Nov 12, 2025Q3 FY25	$0.03	$0.04	+33.3%	$21.5M	$21.6M	+0.2%	0.00%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$18.6M	$19.1M	$21.6M	$22.8M	$28.0M	$28.3M
Gross profit	$11.7M	$11.8M	$12.2M	$10.9M	$15.6M	$17.9M
Operating income	$2.5M	$1.4M	$1.6M	$1.9M	$6.7M	$7.0M
Net income	$2.6M	$1.4M	$2.2M	$1.4M	$5.4M	$6.8M
Diluted EPS	$0.05	$0.02	$0.04	$0.02	$0.09	$0.11
Gross margin	62.9%	61.6%	56.3%	48.0%	55.6%	63.3%
Operating margin	13.4%	7.5%	7.3%	8.1%	23.8%	24.8%

Fiscal years (4-quarter sums)FY21 $29.5M · FY22 $38.0M · FY23 $47.3M · FY24 $58.4M · FY25 $82.0M

Revenue by product · Q2 FY26

Pharma Industry$14.6M · 52%

Plasma Industry$13.0M · 46%

Other Revenue$562.4K · 2%

Balance sheet, Jun 30, 2026Cash & short-term investments $27.4M · Total debt $5.7M · Total assets $317.0M · Shareholders' equity $60.2M

Dividends

No dividends on record.

Ownership

Institutions 46.42%25.95M sharesInsiders 21.47%12.00M sharesOther 32.11%17.95M shares

Shares outstanding 55.91M · Float 34.17M · 61.1% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Mark Newcomer · director, 10 percent owner, officer: CEO	9.16M	16.39%	Form 4	Aug 7, 2026
Topline Capital Management, LLC	4.64M	8.30%	13F	May 15, 2026
Spence Daniel · 10 percent owner	4.30M	7.68%	Form 4	Mar 25, 2025
BlackRock, Inc.	3.03M	5.40%	13G	Jul 29, 2026
Punch & Associates Investment Management, Inc.	2.06M	3.68%	13F	May 15, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Aug 12, 2026	Jeffery Bradford Baker	officer: Chief Financial Officer	−35,000	$12.62
Aug 6, 2026	Mark Newcomer	director, 10 percent owner, officer: CEO	−150,000	$11.88
Jul 29, 2026	Mark Newcomer	director, 10 percent owner, officer: CEO	−50,000	$9.38
Jun 11, 2026	Bruce A. Mina	director	−10,000	$7.10
Jun 1, 2026	Bruce A. Mina	director	−10,000	$7.10